Autopsy report · NCT06653023

Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer

“Because the implementation of the new regulation policy by the Chinese authority”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 60 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Early Phase 1

Sponsor

Wondercel Biotech (ShenZhen)

Sponsor type

Industry

Conditions

HCC - Hepatocellular Carcinoma; NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

Universal CAR-T cells injection for treating HCC and NSCLC; MMF Immunosuppression

Participants

60 (planned, not actual)

Sites

1

Countries

China

Trials that died the same way

• Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients
  “Changes in country regulation” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.